The primary goal of the Mass Spectrometry Resource (MSR) is to provide comprehensive mass spectral and, in the near future, biophysical analyses to investigate within the YCC. The instrumentation required to meet this goal is invariably expensive and requires considerable expertise to operate and to properly interpret the resulting data. The Resource is equipped with a VG-ZAB-SE high resolution, high mass range mass spectrometer equipped with EI and FAB (35 kV Cesium ion) ion sources. The instrument is used to provide low and high resolution mass spectral analyses. The Resource has a Micro-mass Quattro model triple quadrupole instrument equipped with an electrospray ion source manufactured by Analytica, Inc(Branford, CT). This ion source also contains a nanoflow probe. Samples can be introduced by either direct infusion or by HPLC. The Resource is also affiliated with the W.M. Keck Biotechnology Resource in which are housed a Finnegan LCQ and a Micro-mass TofSpec MALDI mass spectrometers ensuring that a wide variety of mass spectral instrumentation can be applied to any sample. The Resource welcomes inquires on the applicability of mass spectrometry to a particular bioanalytical problem. The operation of the MSR is supported by users fees, the Cancer Center Support Grant and the YCC. Questions can be addressed to Walter McMurray at 203-785-6169 or by e-mail at walter.mcmurray@yale.edu.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-24
Application #
6101781
Study Section
Project Start
1998-09-23
Project End
1999-06-30
Budget Start
Budget End
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996

Showing the most recent 10 out of 675 publications